Bruker Launches Novel timsMetabo ™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale
Breakthrough timsMetabo Performance with MoRE
The benchtop timsMetabo system combines unique and powerful trappped ion mobility separation (TIMS) technology and time-focussing for exceptional sensitivity. Novel Mobility Range Enhancement (MoRE) acquisition leverages the enhanced ion capacity of the dual-stage TIMS-MX ion funnel, expanding its mass-to-charge and mobility ranges. Coupled with a new high-precision quadrupole and the innovative Athena Ion Processor (AIP), the timsMetabo is the next-generation 4D-Metabolomics research and validation workhorse for unprecedented confidence in small molecule analysis in complex mixtures – with sensitivity at speed and scale.
The timsMetabo excels at resolving isomers, isobars, and interferences in routine operation owing to its unique additional real-time gas phase CCS ion separation capability, delivering highly-selective MS1-based quantification – at speed and scale.
For assays requiring precision at the limit of quantitation, the AIP-equipped timsMetabo provides cleaner, less-chimeric MS/MS acquisition at rates up to 300 Hz for targeted quantitative analysis using parallel reaction monitoring. The AIP leverages mobility information encoded by TIMS in each acquisition cycle for optimal transfer of MS and MS/MS-derived ions for TOF mass analysis.
These novel features synergistically produce a rich digital metabolome archive of metabolite identity and quantity from each sample, enabling confident analysis, and enabling AI in metabolomics with machine learning from large-scale, high-quality data sets. The timsMetabo supports both HESI and CSI ion sources for coupling with analytical flow, microflow and nanoflow high-performance liquid chromatography.
Dr. Frédéric Vaz, Associate Professor and Head of the Core Facility Metabolomics (CFM) at University of Amsterdam Medical Center, said: 'The timsMetabo uniquely combines sensitivity and selectivity, facilitating measurement of both, known biomarkers and the exploration of new metabolic signatures in research on inborn errors of metabolism. This performance versatility in a single instrument accelerates our research in expanding our knowledge of human metabolism from a clinical/translational perspective towards our ultimate goal to use such technologies to unravel pathologic mechanism of disease and promote new therapeutic strategies for both inherited and acquired disorders.'
Prof. Pieter Dorrestein, Professor at the University of San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, Director, Collaborative Mass Spectrometry Innovation Center and Co-Director, Institute for Metabolomics Medicine, commented: ' Bile acids are a diverse and biologically important class of molecules involved in nutrient transport, immune regulation, and are altered in response to medications, diet, and disease. Thousands of distinct bile acid structures – including newly discovered microbially modified forms – are now being revealed. Ion mobility, enhanced by reproducible CCS values at scale, alongside chromatography and MS/MS, is unlocking this hidden complexity, advancing our understanding of bile acid biology, clinical research, and therapeutic discovery. The technology within the timsMetabo will help us better understand this biologically diverse class of molecules routinely, at speed and scale, and this is an exciting combination.'
QSee™ quality control suite by Bruker
Bruker also launches the QSee quality control (QC) suite of software and reference materials for automated evaluation of instrument performance and long-term monitoring via cloud-based TwinScape™ software. In partnership with Polymer Factory Sweden AB, the leading manufacturer of stable polymer-based mass spectrometry calibrants, the SpheriCal® platform has been extended to include the new QSee 8-mix for assessment of chromatographic and mass spectrometry performance. Results are archived for comparison across time using the TwinScape cloud-based solution already available for proteomics.
Dr. Christoph Trautwein, Director of the Core Facility Metabolomics at University of Tübingen, commented: 'By integrating QSee Performance Testing into our lab routine, we're conveniently benchmarking our LC-TIMS-MS system performance before each experiment. The slim and intuitive workflow makes this a straightforward check, and the results provide assurance and 'peace of mind' that we're consistently producing high quality quantitative data. Confidence in our analytical results has never been higher, thanks to this comprehensive solution. It's truly a QC game-changer for our metabolomics lab.'
Additionally, TASQ®'s RealTimeQC capabilities for within-batch data quality monitoring have been enhanced with improved data visualization including LC system pressure.
Professor Thomas Moritz of the Novo Nordisk Foundation Centre for Basic Metabolic Research at the University of Copenhagen, added: 'Bruker's commitment to making data quality information immediately accessible is evident with TASQ RealTimeQC. Their innovative solution to quality monitoring provides assurance when it matters most and helps us make informed decision during the analysis, before it's too late to act. With RealTimeQC, Bruker is uniquely and directly supporting lab-based metabolomics and lipidomics research."
Dr. Matthew Lewis, VP Metabolomics and Lipidomics at Bruker, concluded: 'The novel timsMetabo represents a step-change in 4D-Metabolomics and 4D-Lipidomics, and a sustained commitment to innovation in these application spaces. With an unrelenting focus, we are elevating our customer's hands-on experience by listening to their needs and delivering unique features in data analysis, confidence in automated metabolite annotation, and informed quality monitoring.'
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Why Investors Are Turning to Freshworks (FRSH) for AI Exposure
Freshworks Inc. (NASDAQ:FRSH) is one of the . On August 11, Oppenheimer analyst Brian Schwartz reiterated an Outperform rating on the stock with a $19.00 price target. The rating affirmation follows a webinar and investor meetings with the company's CFO. Oppenheimer hosted Freshworks CFO Tyler Sloat at its 28th Annual Technology, Internet, and Communications Conference on Monday. The conference included discussions about the company's market aopportunities, artificial intelligence momentum, and competitive positioning. The firm recommends Freshworks to those investors who are looking for exposure to artificial intelligence. 'We hosted a well-attended webinar and investor meetings with Tyler Sloat, CFO of Freshworks, at our 28th Annual Technology, Internet, and Communications Conference earlier today. Management's tone was upbeat as the discussion centered on the company's large and underpenetrated TAM, AI business momentum, growth opportunities and competitive moat in the AI era, its go-to-market strategy with improving efficiency, move into adjacent workflow markets, multi-products adoption, product led growth momentum, stabilization in the CX business, technology updates, and productivity trends." An experienced portfolio manager delivering a presentation to a group of investors. "Following the webinar, we remain positive on Freshworks' business momentum and AI monetization trajectory. Bottom Line: We recommend FRSH for investors looking for exposure to AI, the services modernization and customer/IT engagement themes at a discount valuation versus peers.' Freshworks Inc. is a software development company that provides software-as-a-service products. While we acknowledge the potential of FRSH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Why Analysts Remain Cautious on CoreWeave (CRWV) Despite Strong Growth
CoreWeave, Inc. (NASDAQ:CRWV) is one of the Must-Watch AI Stocks on Wall Street. On August 13, Citizens JMP analyst Greg Miller reiterated a Market Perform rating on the stock without a price target. The rating affirmation reflects CoreWeave's stronger-than-expected results and positively revised outlook. JMP has noted how CoreWeave encompasses a business model that enables cloud and hyperscale companies to manage capital expenditure increases while accelerating time to market for their services. At the same time, it remains cautious about GPU-as-a-Service providers' ability to steer through falling average selling prices and increasing customer churn against rising real estate costs. A financial analyst evaluating the large- and mid-cap U.S. equity market on a digital display. 'CoreWeave reported 2Q25 results that one would expect after such a high-profile IPO; stronger-than-consensus expectations with a positively revised outlook that clearly demonstrates the hyperscale company's willingness to push balance sheet liabilities onto other companies in exchange for a high initial margin (over a 3-4-year term). While we continue to believe cloud/hyperscale companies will accelerate the push to use these companies to help manage capex increases and speed time to market, we remain cautious with regard to GPUaaS providers' abilities to manage a declining ASP and increasing churn against the backdrop of an increasing real estate cost structure. We remain Market Perform rated on CoreWeave, as we wait for investors to gain a better understanding of the underlying KPIs.' CoreWeave, Inc. (NASDAQ:CRWV) is a cloud platform provider that provides equipment for AI and other computing purposes. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
Prediction: Nvidia's New China Deal Will Be a Game-Changer. Here's Why
Key Points While most of Nvidia's revenue hails from the U.S. and Europe, the Chinese market represents an estimated $50 billion opportunity. Recent changes to tariff policies and export controls have stifled Nvidia's potential in China throughout 2025. Nvidia and the U.S. government have formed a deal structure that helps pave the way for Nvidia to reclaim dominance in the key Asian market. 10 stocks we like better than Nvidia › Although it's only August, 2025 has already played out like a modern-day Greek tragedy for semiconductor powerhouse Nvidia (NASDAQ: NVDA). Its year has been marked by a litany of setbacks, comebacks, and everything in between. Earlier this year, more than $1 trillion of Nvidia's market value was wiped out. Yet today, the company boasts a market cap of $4.4 trillion -- reclaiming the crown as the most valuable company in the world. At the center of Nvidia's headaches in 2025 is China -- and no, not because of DeepSeek. The real culprit has been a wave of sweeping tariff policies and export controls that have curtailed Nvidia's influence in the Chinese AI market. Now, after months of negotiations with regulators in Washington, it appears that the tide may be turning. Nvidia could be on the precipice of reestablishing its presence in one of its most crucial Asian markets. Let's unpack the details of Nvidia's new deal structure in China and examine why it should be celebrated as a massive win for investors. How big an opportunity is China for Nvidia? According to accounting and consulting firm Deloitte, the global total addressable market (TAM) for semiconductors, as measured by sales, reached $627 billion in 2024. Deloitte projects that the market will grow at a compound annual growth rate (CAGR) of 19% over the coming decades -- ultimately reaching $2 trillion by 2040. Outside of the U.S., China remains one of the most important markets fueling demand for high-performance chipsets, particularly graphics processing units (GPUs). Nvidia CEO Jensen Huang has estimated that the AI opportunity in China alone could be worth as much as $50 billion. In 2024, Nvidia generated $130 billion in revenue, with China capturing roughly 13% of this sum. During the first quarter of 2025, Nvidia's $5.5 billion of China sales accounted for roughly 12.5% of total revenue. This leveling trend underscores how the current administration's policies toward China have started to constrain Nvidia's growth potential in the region. Why is Nvidia's new China deal so important? According to multiple news outlets, Nvidia has reached an agreement with Washington regarding its operation in China. Under the terms, Nvidia will pay 15% of its China-based sales to the U.S. government. In effect, the arrangement provides Nvidia with a pathway to penetrate this critical market through its tailored H20 chips. While this might initially resemble a tax, investors should avoid viewing it through that lens. First, the agreement applies to sales of Nvidia's AI chips rather than to profits, unlike traditional forms of taxation. Moreover, the 15% rate does not appear to be variable in structure like a royalty, which is typically tied to intellectual property (IP) and subject to fluctuate. While this deal might appear unusual at first glance, these structures are not without precedent in global business practices. For example, energy companies that extract natural resources or commodities in foreign countries often operate under similar revenue-sharing agreements with host nations in exchange for distribution rights. In my view, dedicating a modest share of sales to secure access to China represents a strategic trade-off. In the long run, it allows Nvidia to preserve its dominant position in one of the world's most important AI markets and prevents domestic rivals such as Huawei from eroding its competitive moat. Is Nvidia stock a buy? While Nvidia's forward price-to-earnings (P/E) ratio has been expanding recently, levels remain muted compared to peaks reached previously during the AI revolution. In my view, part of this multiple compression reflects concerns surrounding China -- perhaps overly so. Nvidia's new agreement in Washington offers the company renewed momentum, securing revenue in a critical market without forfeiting much in the way of profits -- even with the 15% remittance to the U.S. government. Over the long term, I see this arrangement as a strategic mechanism for Nvidia to strengthen its position overseas and deliver durable growth across the global AI infrastructure market. As these fundamentals take hold, I think the company's valuation multiples could expand further, potentially driving the stock to new highs sooner than many investors may be expecting. For that reason, I see Nvidia stock as a no-brainer opportunity to buy hand over fist right now and hold for years to come. Do the experts think Nvidia is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nvidia make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,070% vs. just 184% for the S&P — that is beating the market by 885.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Adam Spatacco has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Prediction: Nvidia's New China Deal Will Be a Game-Changer. Here's Why was originally published by The Motley Fool Sign in to access your portfolio
